News Image

Cytokinetics Presents New Data Related to Aficamten at the European Society of Cardiology Congress 2025

Provided By GlobeNewswire

Last update: Aug 31, 2025

Additional Data from MAPLE-HCM Shows Aficamten Improves Cardiac Structure and Function Compared to Metoprolol; Simultaneous Publication in the Journal of the American College of Cardiology

Read more at globenewswire.com

CYTOKINETICS INC

NASDAQ:CYTK (12/5/2025, 8:12:30 PM)

After market: 65.67 0 (0%)

65.67

-0.87 (-1.31%)



Find more stocks in the Stock Screener

Follow ChartMill for more